Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Codexis Licenses Enzymes To GSK
by Ann M. Thayer
July 21, 2014
| A version of this story appeared in
Volume 92, Issue 29
Biocatalyst developer Codexis has licensed its enzyme engineering technology to GlaxoSmithKline for making pharmaceuticals and other health care products. GSK will pay Codexis $6 million up front and another $19 million over two years as it transfers the technology to its Upper Merion, Pa., R&D site. Under the license, GSK can use the technology to develop enzymes for manufacturing processes and to create therapeutic, diagnostic, and prophylactic products. Codexis could receive milestone payments of up to $39 million per project, plus royalties, if GSK is successful in using the technology.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter